This company has been marked as potentially delisted and may not be actively trading. Sinovac Biotech (SVA) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesOptions ChainTrendsBuy This Stock SVA vs. MLTX, HCM, ACAD, APLS, AMRX, BHVN, FOLD, MTSR, LGND, and SDGRShould you be buying Sinovac Biotech stock or one of its competitors? The main competitors of Sinovac Biotech include MoonLake Immunotherapeutics (MLTX), HUTCHMED (HCM), ACADIA Pharmaceuticals (ACAD), Apellis Pharmaceuticals (APLS), Amneal Pharmaceuticals (AMRX), Biohaven (BHVN), Amicus Therapeutics (FOLD), Metsera (MTSR), Ligand Pharmaceuticals (LGND), and Schrödinger (SDGR). These companies are all part of the "pharmaceutical preparations" industry. Sinovac Biotech vs. MoonLake Immunotherapeutics HUTCHMED ACADIA Pharmaceuticals Apellis Pharmaceuticals Amneal Pharmaceuticals Biohaven Amicus Therapeutics Metsera Ligand Pharmaceuticals Schrödinger MoonLake Immunotherapeutics (NASDAQ:MLTX) and Sinovac Biotech (NASDAQ:SVA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, community ranking, analyst recommendations and dividends. Does the MarketBeat Community favor MLTX or SVA? Sinovac Biotech received 189 more outperform votes than MoonLake Immunotherapeutics when rated by MarketBeat users. However, 81.93% of users gave MoonLake Immunotherapeutics an outperform vote while only 67.99% of users gave Sinovac Biotech an outperform vote. CompanyUnderperformOutperformMoonLake ImmunotherapeuticsOutperform Votes6881.93% Underperform Votes1518.07%Sinovac BiotechOutperform Votes25767.99% Underperform Votes12132.01% Is MLTX or SVA more profitable? Sinovac Biotech's return on equity of 0.00% beat MoonLake Immunotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets MoonLake ImmunotherapeuticsN/A -15.54% -15.09% Sinovac Biotech N/A N/A N/A Which has higher valuation and earnings, MLTX or SVA? MoonLake Immunotherapeutics has higher earnings, but lower revenue than Sinovac Biotech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMoonLake ImmunotherapeuticsN/AN/A-$36.01M-$1.89-20.86Sinovac Biotech$448.27M1.44-$99.92MN/AN/A Do institutionals and insiders hold more shares of MLTX or SVA? 93.8% of MoonLake Immunotherapeutics shares are owned by institutional investors. 12.0% of MoonLake Immunotherapeutics shares are owned by company insiders. Comparatively, 12.8% of Sinovac Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media favor MLTX or SVA? In the previous week, MoonLake Immunotherapeutics had 5 more articles in the media than Sinovac Biotech. MarketBeat recorded 11 mentions for MoonLake Immunotherapeutics and 6 mentions for Sinovac Biotech. MoonLake Immunotherapeutics' average media sentiment score of 0.92 beat Sinovac Biotech's score of 0.00 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MoonLake Immunotherapeutics 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sinovac Biotech 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate MLTX or SVA? MoonLake Immunotherapeutics presently has a consensus target price of $80.50, indicating a potential upside of 104.21%. Given MoonLake Immunotherapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe MoonLake Immunotherapeutics is more favorable than Sinovac Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MoonLake Immunotherapeutics 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00Sinovac Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk & volatility, MLTX or SVA? MoonLake Immunotherapeutics has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500. Comparatively, Sinovac Biotech has a beta of 0.01, meaning that its stock price is 99% less volatile than the S&P 500. SummaryMoonLake Immunotherapeutics beats Sinovac Biotech on 10 of the 15 factors compared between the two stocks. Get Sinovac Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for SVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SVA vs. The Competition Export to ExcelMetricSinovac BiotechPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$644.67M$6.68B$5.44B$7.80BDividend YieldN/A3.17%5.43%4.31%P/E RatioN/A7.1422.1418.40Price / Sales1.44238.89389.70101.29Price / Cash38.9565.6738.2034.62Price / Book0.056.266.664.18Net Income-$99.92M$142.48M$3.21B$247.71M Sinovac Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SVASinovac BiotechN/A$6.47flatN/AN/A$644.67M$448.27M0.003,261High Trading VolumeMLTXMoonLake Immunotherapeutics2.0071 of 5 stars$40.00+4.4%$80.50+101.3%-6.7%$2.56BN/A-31.012News CoverageHCMHUTCHMED2.1767 of 5 stars$13.89+0.9%$19.00+36.8%-23.1%$2.42B$630.20M0.001,760News CoverageACADACADIA Pharmaceuticals3.9771 of 5 stars$14.38-2.4%$23.93+66.4%-9.7%$2.40B$957.80M18.44510Positive NewsAPLSApellis Pharmaceuticals4.0923 of 5 stars$18.03-0.9%$45.35+151.5%-63.5%$2.26B$781.37M-8.88770Positive NewsAMRXAmneal Pharmaceuticals3.1114 of 5 stars$7.13-3.1%$10.80+51.5%+26.8%$2.21B$2.79B-10.497,600Positive NewsBHVNBiohaven3.5622 of 5 stars$20.67+1.5%$62.77+203.7%-48.6%$2.11BN/A-2.21239Options VolumeGap DownFOLDAmicus Therapeutics4.0748 of 5 stars$6.71-1.8%$16.75+149.6%-27.7%$2.10B$528.30M-37.28480Upcoming EarningsPositive NewsMTSRMetseraN/A$19.51-0.3%$47.00+140.9%N/A$2.05BN/A0.0081Gap UpHigh Trading VolumeLGNDLigand Pharmaceuticals4.3964 of 5 stars$104.81-0.2%$146.43+39.7%+53.6%$2.02B$167.13M41.7680News CoveragePositive NewsSDGRSchrödinger1.5982 of 5 stars$26.19+1.7%$33.00+26.0%+13.3%$1.91B$207.54M-11.19790Upcoming EarningsPositive News Related Companies and Tools Related Companies MLTX Alternatives HCM Alternatives ACAD Alternatives APLS Alternatives AMRX Alternatives BHVN Alternatives FOLD Alternatives MTSR Alternatives LGND Alternatives SDGR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SVA) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredIt’s absolute chaos in Silicon Valley right now…If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sinovac Biotech Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sinovac Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SVA Stock Free SVA Stock Alerts